Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

600 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
Stelljes M, Raffel S, Alakel N, Wäsch R, Kondakci M, Scholl S, Rank A, Hänel M, Spriewald B, Hanoun M, Martin S, Schwab K, Serve H, Reiser L, Knaden J, Pfeifer H, Marx J, Sauer T, Berdel WE, Lenz G, Brüggemann M, Gökbuget N, Wethmar K. Stelljes M, et al. Among authors: lenz g. J Clin Oncol. 2024 Jan 20;42(3):273-282. doi: 10.1200/JCO.23.00546. Epub 2023 Oct 26. J Clin Oncol. 2024. PMID: 37883727 Clinical Trial.
Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress.
Gomez Solsona B, Horn H, Schmitt A, Xu W, Bucher P, Heinrich A, Kalmbach S, Kreienkamp N, Franke M, Wimmers F, Schuhknecht L, Rosenwald A, Zampieri M, Ott G, Lenz G, Schulze-Osthoff K, Hailfinger S. Gomez Solsona B, et al. Among authors: lenz g. Blood Adv. 2023 Dec 26;7(24):7433-7444. doi: 10.1182/bloodadvances.2023010964. Blood Adv. 2023. PMID: 37934892 Free PMC article.
Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study.
Berning P, Shumilov E, Maulhardt M, Boyadzhiev H, Kerkhoff A, Call S, Reicherts C, Saidy AO, Aydilek E, Hoffmann M, Novak U, Daskalakis M, Schmitz N, Stelljes M, Wulf G, Bacher U, Lenz G, Pabst T. Berning P, et al. Among authors: lenz g. Hemasphere. 2024 Mar 20;8(3):e54. doi: 10.1002/hem3.54. eCollection 2024 Mar. Hemasphere. 2024. PMID: 38510993 Free PMC article.
Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.
Patra-Kneuer M, Chang G, Xu W, Augsberger C, Grau M, Zapukhlyak M, Ilieva K, Landgraf K, Mangelberger-Eberl D, Yousefi K, Berning P, Kurz KS, Ott G, Klener P, Khandanpour C, Horna P, Schanzer J, Steidl S, Endell J, Heitmüller C, Lenz G. Patra-Kneuer M, et al. Among authors: lenz g. Front Immunol. 2023 Jul 31;14:1220558. doi: 10.3389/fimmu.2023.1220558. eCollection 2023. Front Immunol. 2023. PMID: 37600821 Free PMC article.
Dose-dependent effect of GFI1 expression in the reconstitution and the differentiation capacity of HSCs.
Xie X, Patnana PK, Frank D, Schütte J, Al-Matary Y, Künstner A, Busch H, Ahmed H, Liu L, Engel DR, Dührsen U, Rosenbauer F, Von Bubnoff N, Lenz G, Khandanpour C. Xie X, et al. Among authors: lenz g. Front Cell Dev Biol. 2023 Apr 5;11:866847. doi: 10.3389/fcell.2023.866847. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37091981 Free PMC article.
600 results